Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
Authors
Keywords
-
Journal
Viruses-Basel
Volume 13, Issue 2, Pages 173
Publisher
MDPI AG
Online
2021-01-26
DOI
10.3390/v13020173
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
- (2020) Yixuan J. Hou et al. CELL
- Lack of Antiviral Activity of Darunavir against SARS-CoV-2
- (2020) Sandra De Meyer et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2—a molecular dynamic study
- (2020) Muhammad Tahir Khan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle
- (2020) Clarisse Salgado-Benvindo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of M Protease inhibitors encoded by SARS-CoV-2
- (2020) Hui-Chen Hung et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
- (2020) Natalia Fintelman-Rodrigues et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro)
- (2020) Abbas Khan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice
- (2020) Athri D. Rathnayake et al. Science Translational Medicine
- The SARS-CoV-2 main protease as drug target
- (2020) Sven Ullrich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2
- (2020) Qiang Wang et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay
- (2020) Heather M. Froggatt et al. JOURNAL OF VIROLOGY
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2020) Peter W Horby et al. LANCET
- GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection
- (2020) Shin-ichiro Hattori et al. mBio
- Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
- (2020) Lifeng Fu et al. Nature Communications
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
- (2020) Qingxin Li et al. Microorganisms
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
- (2020) Wen Cui et al. Frontiers in Molecular Biosciences
- NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells
- (2015) Andrew S. Dixon et al. ACS Chemical Biology
- Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis
- (2015) F. X. Schaub et al. CANCER RESEARCH
- Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses
- (2012) Y. Kim et al. JOURNAL OF VIROLOGY
- Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
- (2008) Arun K. Ghosh et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now